Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, systematický přehled
PubMed
31416571
DOI
10.1016/j.mrrev.2019.05.002
PII: S1383-5742(19)30008-0
Knihovny.cz E-zdroje
- Klíčová slova
- Biomarker, Cancer, Cell-free DNA, Circulating-tumor DNA, Liquid biopsy,
- MeSH
- lidé MeSH
- nádorové biomarkery genetika MeSH
- nádory diagnóza genetika patologie MeSH
- prognóza MeSH
- tekutá biopsie metody MeSH
- volné cirkulující nukleové kyseliny genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- systematický přehled MeSH
- Názvy látek
- nádorové biomarkery MeSH
- volné cirkulující nukleové kyseliny MeSH
The development of minimally invasive and low-cost assay enabling early diagnosis, treatment response and prognosis in cancer patients may provide a promising alternative to tumor biopsy. Circulating cell-free DNA (cfDNA) is probably the most promising tool among all components of liquid biopsy. This review includes studies exploring cfDNA as the diagnostic, prognostic or predictive biomarker for all types of cancer. In this article, we systematically reviewed the relevant literature from PubMed about cfDNA. All articles presented higher cfDNA concentration in cancer patients when compared with patients with benign disease or healthy individuals. Most of the articles showed a connection between cfDNA and prognosis. The presence of high cfDNA level in serum or plasma was associated with worse overall patient's survival. This review supports the idea that the cfDNA analysis represents a promising research area and hopefully in the future, could be applied as a new biomarker for cancer detection, prognosis determination and prediction of the response to therapy.
Citace poskytuje Crossref.org
Colorectal Adenomas-Genetics and Searching for New Molecular Screening Biomarkers
